Qunibi WY - Search Results

1

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B. Kosiborod M, et al. Among authors: qunibi wy. JAMA. 2014 Dec 3;312(21):2223-33. doi: 10.1001/jama.2014.15688. JAMA. 2014. PMID: 25402495 Clinical Trial.

2

Sodium zirconium cyclosilicate in hyperkalemia.

Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B. Packham DK, et al. N Engl J Med. 2015 Jan 15;372(3):222-31. doi: 10.1056/NEJMoa1411487. Epub 2014 Nov 21. N Engl J Med. 2015. PMID: 25415807 Free article. Clinical Trial.

3

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. Qunibi WY, et al. Nephrol Dial Transplant. 2011 May;26(5):1599-607. doi: 10.1093/ndt/gfq613. Epub 2010 Oct 7. Nephrol Dial Transplant. 2011. PMID: 20929915 Free PMC article. Clinical Trial.

4

An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.

Takkar C, Nassar T, Qunibi W. Takkar C, et al. Expert Opin Pharmacother. 2021 Jan;22(1):19-28. doi: 10.1080/14656566.2020.1810234. Epub 2020 Sep 7. Expert Opin Pharmacother. 2021. PMID: 32892634 Review.

5

Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.

Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, Iftikhar H, Mangoo-Karim R, Martin ER, Martinez CO, Newman GE, Qunibi WY, Ross DL, Singh B, Smith MT, Butcher A, Koch TA, Goodnough LT. Onken JE, et al. Among authors: qunibi wy. Nephrol Dial Transplant. 2014 Apr;29(4):833-42. doi: 10.1093/ndt/gft251. Epub 2013 Aug 20. Nephrol Dial Transplant. 2014. PMID: 23963731 Clinical Trial.

6

A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease.

Qunibi W, Winkelmayer WC, Solomon R, Moustafa M, Kessler P, Ho CH, Greenberg J, Diaz-Buxo JA. Qunibi W, et al. BMC Nephrol. 2011 Feb 16;12:9. doi: 10.1186/1471-2369-12-9. BMC Nephrol. 2011. PMID: 21324193 Free PMC article. Clinical Trial.

7

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR. Qunibi WY, et al. Kidney Int. 2004 May;65(5):1914-26. doi: 10.1111/j.1523-1755.2004.00590.x. Kidney Int. 2004. PMID: 15086935 Free article. Clinical Trial.

8

Treatment of vitamin D deficiency/insufficiency with ergocalciferol is associated with reduced vascular access dysfunction in chronic hemodialysis patients.

Agarwal G, Vasquez K, Penagaluru N, Gelfond J, Qunibi WY. Agarwal G, et al. Among authors: qunibi wy. Hemodial Int. 2015 Oct;19(4):499-508. doi: 10.1111/hdi.12292. Epub 2015 Mar 19. Hemodial Int. 2015. PMID: 25790374

9

Dyslipidemia in Dialysis Patients.

Qunibi WY. Qunibi WY. Semin Dial. 2015 Jul-Aug;28(4):345-53. doi: 10.1111/sdi.12375. Epub 2015 Apr 9. Semin Dial. 2015. PMID: 25855389 Review.

10

Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications.

Brezina B, Qunibi WY, Nolan CR. Brezina B, et al. Among authors: qunibi wy. Kidney Int Suppl. 2004 Sep;(90):S39-45. doi: 10.1111/j.1523-1755.2004.09007.x. Kidney Int Suppl. 2004. PMID: 15296506 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page